Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2287352
下载链接
链接失效反馈官方服务：
资源简介：
The main purpose of this study is to test the safety, tolerable side effects, and determine the highest tolerable dose of the combination of Regorafenib and Nivolumab. Researchers want to find out if this combination of Regorafenib and Nivolumab can help people with metastatic colorectal cancer with mismatch repair (MMR) proficiency.
创建时间：
2018-10-15
